<DOC>
	<DOC>NCT02625610</DOC>
	<brief_summary>The purpose of this study is to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.</brief_summary>
	<brief_title>Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100)</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Male or female subjects aged greater than or equal to (&gt;=) 18 years Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) Subjects with histologically confirmed unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GEJ) Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry Estimated life expectancy of more than 12 weeks Adequate haematological, hepatic and renal functions defined by the protocol Negative blood pregnancy test at Screening for women of childbearing potential Highly effective contraception for both male and female subjects if the risk of conception exists Other protocol defined inclusion criteria could apply Prior therapy with any antibody or drug targeting Tcell coregulatory proteins Concurrent anticancer treatment or immunosuppressive agents Prior chemotherapy for unresectable locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction (GEJ) Known severe hypersensitivity reactions to monoclonal antibodies, any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma) Persisting toxicity related to prior therapy except alopecia Neuropathy Grade greater than (&gt;) 3 Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Avelumab</keyword>
	<keyword>Cancer</keyword>
	<keyword>Unresectable</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Adenocarcinoma of the stomach</keyword>
	<keyword>Gastro-esophageal junction</keyword>
</DOC>